Detalles de la búsqueda
1.
Surgical Outcomes After Neoadjuvant Chemoradiation Followed by Curative Surgery in Patients With Esophageal Cancer: An Intergroup Phase III Trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08).
Ann Surg
; 275(6): 1130-1136, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33055589
2.
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
Blood
; 134(4): 353-362, 2019 07 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-31101627
3.
Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy.
Br J Haematol
; 189(4): 707-717, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32012230
4.
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08.
BMC Cancer
; 20(1): 166, 2020 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-32111181
5.
Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial.
Ann Surg Oncol
; 25(9): 2632-2640, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29948418
6.
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Haematologica
; 101(3): 346-55, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26659919
7.
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
Blood
; 132(19): 2097-2100, 2018 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30237154
8.
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Oncol
; 9(10): 1381-1389, 2023 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37561451
9.
SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients.
Endocr Oncol
; 2(1): 9-18, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37435469
10.
Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Radiat Oncol
; 14(1): 166, 2019 Sep 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31511012
11.
Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort.
Sci Rep
; 9(1): 13534, 2019 09 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31537812
12.
Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
Trials
; 19(1): 667, 2018 Dec 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30514362
13.
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Eur J Cancer
; 96: 6-16, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29660598
14.
Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients.
Endocr Connect
; 6(7): 549-556, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28814476
15.
Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia.
Hum Pathol
; 36(1): 91-100, 2005 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-15712187
16.
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
Eur J Cancer
; 51(10): 1212-20, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25892646
Resultados
1 -
16
de 16
1
Próxima >
>>